Sector News

Shareholder asks Amgen to split into two businesses

October 22, 2014
Life sciences
Amgen is keeping its own counsel after one major investors, hedge fund Third Point, urged the biotech to consider splitting into two separate businesses.
 
High-profile activist investor and Third Point founder Daniel Loeb sent out a letter to backers about Amgen, claiming that the fund is now “one of the company’s largest shareholders”. He wrote that “the obscured fundamental value and investor scepticism that have led to Amgen’s valuation discount can be easily unlocked, saying the biotech needs to focus its R&D efforts and reduce “a bloated cost structure”.
 
Aside from this, however, Mr Loeb is in favour of “a more radical” approach, namely splitting the company in two, one being Amgen’s “assets–cash‐generative mature products and the other an “R&D‐intensive growth products” unit.
 
The letter says Amgen stock could get to $189 a share by the end of 2016 and $218 by the end of 2017 if the company cuts costs and makes R&D more efficient. However, with a split, Third Point believes it could be worth $249 a share in two years; Amgen ended the day up 4.8% after the hedge fund report at $144.09.
 
Board described as ‘open-minded’ by Loeb
 
Mr Loeb was not making an aggressive attack and praised Amgen for taking some steps to cut costs, describing the board as being “open‐minded and receptive to our ideas”. Still, “we firmly believe that the company is at an inflection point,” he wrote, and “we hope to maintain our constructive dialogue with management as the company moves towards closing its valuation gap”.
 
Amgen quickly released a statement “with respect to media inquiries concerning Third Point equity position in Amgen”, saying it has “always appreciated the perspectives of all of its shareholders, including Third Point, and welcomes constructive input toward our common goal of enhancing shareholder value”.
 
The firm added that the board “frequently receives input from shareholders, including ideas like those offered by Third Point” and “continually assess Amgen’s strategic priorities – and, when appropriate, take action”. More on Amgen’s “strategic priorities and update on our restructuring plans” will be laid out “at our business review on October 28”.
 
By Kevin Grogan
 
Source: Pharma Times

Related News

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]

September 15, 2020

Gilead to buy Immunomedics for $21bn

Life sciences

Gilead Sciences has announced plans to acquire Immunomedics in a deal valued at $21 billion. Under the agreement, which has been unanimously approved by both boards of directors, Gilead will […]